Anal Cancer News and Research

RSS

Anal cancer is a type of cancer which arises from the anus, the distal orifice of the gastrointestinal tract. It is a distinct entity from the more common colorectal cancer.

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

A UC San Francisco investigator has won an eight-year grant from the National Cancer Institute for a major investigation into anal cancer, a debilitating and sometimes fatal disease largely concentrated among people with HIV.

25 Nov 2013

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

A study of 2,519 Kenyan men conducted by researchers at the University of North Carolina revealed that infection with the human papillomavirus (HPV) was associated with a higher subsequent risk of infection with HIV, a precursor to AIDS.

25 Nov 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

17 Aug 2013

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

P53 is a tumor suppressor gene. The gene encodes for a protein that monitors the state of the cell. If something goes wrong, it stops the cell from dividing or causes the cell to commit suicide. I call it the “guardian of the genome” as it is the molecule that seems to keep cells normal. It is one of our big defenses against cancer.

22 Jul 2013

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health.

19 Jul 2013

Scientists find high prevalence of HPV infection in oral, anal and penile cavities in HIV-positive men

Scientists in Barcelona have found a high presence of papillomavirus infection in oral, anal and penile cavities in HIV-positive men, particularly in the anal cavities of men who have homosexual sex. The researchers recommend routine examination of the three areas in all men, independently of their sexual behaviour.

27 Jun 2013

Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Our current method, which is recommended by the Association of Breast Surgeons in the UK, involves the use of injections of blue dye and radioisotope to identify the first node(s) under the arm (axilla) called the sentinel nodes.

25 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Cleveland Clinic receives $2M for research in colorectal surgery

Kenneth M. Garschina and his wife, Sara Story, have pledged $2 million to Cleveland Clinic's Digestive Disease Institute to create an endowed chair for research in colorectal surgery. The donation coincides with the re-dedication of two previously funded endowed chairs.

6 May 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research 2013 Annual Meeting.

10 Apr 2013

Scientists figure out how to dodge HPV-triggered cancers by vaccination

In 2009, more than 30,000 people in the U.S. learned they had cancer linked to the human papillomavirus, or HPV. This virus is best known for causing cervical cancer, but it's also the culprit behind many cancers of the mouth, throat, anus, and genitals. Unlike many forms of cancer, for which we lack the knowledge and tools to prevent, scientists have figured out how to dodge HPV-triggered cancers — by HPV vaccination.

19 Jan 2013

Study to determine prevalence of abnormal anal cytology and HPV in at-risk women

A basic connection of statistics lead a researcher at Women & Infants Hospital of Rhode Island to question whether women should be screened for anal cancer during a regular visit to the gynecologist, and what technique is most effective.

18 Jan 2013

Overall cancer death rates continue to decline in the U.S.: Report

The Annual Report to the Nation on the Status of Cancer, 1975-2009, shows that overall cancer death rates continued to decline in the United States among both men and women, among all major racial and ethnic groups, and for all of the most common cancer sites, including lung, colon and rectum, female breast, and prostate.

9 Jan 2013

Anal Cancer News and Research

Further Reading

UCSF investigator receives $89 M grant to research on anal cancer in people with HIV

Research reveals that HPV infection is associated with higher subsequent risk of HIV infection

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

p53 and cancer research: an interview with Professor Sir David Lane, Scientific Director of the Ludwig Institute for Cancer Research

Boys more likely to receive HPV4 vaccine if their mothers receive flu shots, study finds

Scientists find high prevalence of HPV infection in oral, anal and penile cavities in HIV-positive men

Sentinel lymph node biopsy for early breast cancer: an interview with Prof. Gordon Wishart, Anglia Ruskin University

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Cleveland Clinic receives $2M for research in colorectal surgery

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis to license its ADXS-HPV product candidate to FusionVax

BIND Therapeutics presents positive Phase 1 clinical study results for BIND-014 at AACR meeting

Scientists figure out how to dodge HPV-triggered cancers by vaccination

Study to determine prevalence of abnormal anal cytology and HPV in at-risk women

Overall cancer death rates continue to decline in the U.S.: Report

Infrared therapy could help prevent anal cancer in HIV-positive population

HIV infection has been major driver of anal cancer burden

Study determines impact of HIV on anal cancer incidence in the U.S.

Rare study highlights anal cancer prognosis risks

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News